BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Stock Position Reduced by Swiss National Bank

Swiss National Bank trimmed its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 10.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 373,468 shares of the biotechnology company’s stock after selling 41,900 shares during the quarter. Swiss National Bank owned approximately 0.18% of BioCryst Pharmaceuticals worth $2,237,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 15,392,319 shares of the biotechnology company’s stock valued at $108,978,000 after buying an additional 302,270 shares during the last quarter. Braidwell LP raised its position in shares of BioCryst Pharmaceuticals by 92.1% during the 3rd quarter. Braidwell LP now owns 5,362,980 shares of the biotechnology company’s stock worth $37,970,000 after purchasing an additional 2,571,100 shares during the period. Deerfield Management Company L.P. Series C lifted its holdings in shares of BioCryst Pharmaceuticals by 148.6% in the 3rd quarter. Deerfield Management Company L.P. Series C now owns 3,286,000 shares of the biotechnology company’s stock worth $23,265,000 after purchasing an additional 1,964,000 shares during the last quarter. Kynam Capital Management LP boosted its position in BioCryst Pharmaceuticals by 10.0% during the 3rd quarter. Kynam Capital Management LP now owns 3,133,193 shares of the biotechnology company’s stock valued at $22,183,000 after purchasing an additional 284,996 shares during the period. Finally, Rock Springs Capital Management LP grew its stake in BioCryst Pharmaceuticals by 2.2% during the 3rd quarter. Rock Springs Capital Management LP now owns 2,551,226 shares of the biotechnology company’s stock worth $18,063,000 after buying an additional 54,033 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. JMP Securities raised their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 7th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

BioCryst Pharmaceuticals Trading Down 5.0 %

BCRX stock opened at $6.33 on Friday. The firm’s 50-day moving average is $5.05 and its two-hundred day moving average is $5.49. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -5.92 and a beta of 1.96. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.03 and a 52 week high of $8.96.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter last year, the company earned ($0.28) earnings per share. The business’s revenue for the quarter was up 34.9% on a year-over-year basis. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Insider Activity

In other news, Director Nancy J. Hutson bought 5,000 shares of the stock in a transaction that occurred on Monday, May 20th. The shares were purchased at an average cost of $6.38 per share, with a total value of $31,900.00. Following the completion of the acquisition, the director now directly owns 86,818 shares in the company, valued at $553,898.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other BioCryst Pharmaceuticals news, Director Nancy J. Hutson acquired 5,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 20th. The stock was bought at an average price of $6.38 per share, for a total transaction of $31,900.00. Following the transaction, the director now owns 86,818 shares in the company, valued at approximately $553,898.84. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Steven K. Galson bought 21,940 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was acquired at an average price of $5.49 per share, for a total transaction of $120,450.60. Following the completion of the acquisition, the director now directly owns 51,551 shares in the company, valued at $283,014.99. The disclosure for this purchase can be found here. Insiders bought a total of 93,240 shares of company stock worth $530,342 over the last 90 days. 4.40% of the stock is currently owned by company insiders.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.